Patents by Inventor Wilbur A. Franklin

Wilbur A. Franklin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170029901
    Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.
    Type: Application
    Filed: August 9, 2016
    Publication date: February 2, 2017
    Inventors: Marileila Varella Garcia, Paul A. Bunn, Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch
  • Patent number: 9434994
    Abstract: Disclosed are methods to obtain an expression score to evaluate gene expression in a tissue specimen obtained from a person having or suspected of having cancer.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: September 6, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Marileila Varella Garcia, Paul A. Bunn, Jr., Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch
  • Publication number: 20130004970
    Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.
    Type: Application
    Filed: July 5, 2012
    Publication date: January 3, 2013
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Marileila Varella Garcia, Paul A. Bunn, JR., Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch
  • Publication number: 20120177641
    Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
    Type: Application
    Filed: March 12, 2012
    Publication date: July 12, 2012
    Inventors: Paul A. BUNN, Christopher D. COLDREN, Wilbur A. FRANKLIN, Mark W. GERACI, Barbara A. HELFRICH, Fred R. HIRSCH, Razvan LAPADAT, Michio SUGITA, Samir E. WITTA
  • Patent number: 8017321
    Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: September 13, 2011
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Paul A. Bunn, Jr., Christopher D. Coldren, Wilbur A. Franklin, Mark W. Geraci, Barbara A. Helfrich, Fred R. Hirsch, Razvan Lapadat, Michio Sugita, Samir E. Witta
  • Publication number: 20100196366
    Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
    Type: Application
    Filed: July 23, 2008
    Publication date: August 5, 2010
    Inventors: Paul A. Bunn, Christopher D. Coldren, Wilbur A. Franklin, Mark W. Geraci, Barbara A. Helfrich, Fred R. Hirsch, Razvan Lapadat, Michio Sugita, Samir E. Witta
  • Publication number: 20080113874
    Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
    Type: Application
    Filed: July 23, 2007
    Publication date: May 15, 2008
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Paul A. BUNN, Christopher D. COLDREN, Wilbur A. FRANKLIN, Mark W. GERACI, Barbara A. HELFRICH, Fred R. HIRSCH, Razvan LAPADAT, Michio SUGITA, Samir E. WITTA
  • Publication number: 20080090233
    Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR, protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.
    Type: Application
    Filed: May 26, 2005
    Publication date: April 17, 2008
    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Marileila Varella Garcia, Paul A. Bunn, Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch